Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. (SENS) is a medical technology company in the surgical and medical instrument manufacturing industry, focused on glucose monitoring products for people with diabetes. Company news frequently centers on its long-term implantable continuous glucose monitoring (CGM) systems, Eversense 365 and Eversense E3, which use an under-the-skin sensor, a smart transmitter, and a mobile app to deliver frequent glucose readings.
News updates for SENS often include financial results and revenue updates, such as preliminary unaudited revenue announcements and quarterly earnings reports. These disclosures provide information on revenue trends, new patient growth, and other operating metrics related to the rollout and adoption of Eversense 365 in the United States and other markets.
Investors and observers can also find corporate and capital markets news, including announcements about a 1-for-20 reverse stock split, special stockholder meetings, and the company’s decision to transfer its stock exchange listing from the NYSE American to the Nasdaq Global Select Market. SEC-related press releases, such as those tied to Form 8-K filings, often accompany these events.
Another key category of Senseonics news involves commercialization and partnership developments. The company has reported on its collaboration with Ascensia Diabetes Care and the planned transition of Eversense 365 commercialization and distribution to Senseonics, as well as its work with Sequel MedTech to integrate the Eversense 365 CGM with the twiist automated insulin delivery system. These updates describe how Eversense technology is being deployed and supported in the diabetes care ecosystem.
Visitors to the SENS news page can review these press releases and related updates to follow Senseonics’ progress in long-term implantable CGM technology, its commercialization strategy for Eversense products, and its ongoing financial and corporate reporting. Regularly checking this page can help readers track how the company’s medical device platform and public company activities evolve over time.
Ascensia Diabetes Care announced FDA approval for the next-generation Eversense® E3 Continuous Glucose Monitoring (CGM) System, developed by Senseonics (NYSE American: SENS). This system boasts a sensor life of up to six months, significantly enhancing patient convenience with only two sensor insertions required annually. The E3 sensor demonstrates exceptional accuracy, with a mean absolute relative difference (MARD) of 8.5% from the PROMISE Study. The product aims to launch in the U.S. in Q2 2022, supported by programs to improve patient access and affordability.
Senseonics Holdings, Inc. has announced FDA approval for the Eversense® E3 Continuous Glucose Monitoring (CGM) System, the only long-term implantable CGM, which provides accurate glucose monitoring for up to 6 months. This next-generation device features proprietary SBA technology and is set to be available publicly through Ascensia Diabetes Care in Q2 2022. The company projects 2022 global net revenue between $14 million and $18 million, with ongoing investment in R&D for further product development.
Senseonics Holdings, Inc. (NYSE American: SENS) announced equity grants under its 2019 Inducement Plan to attract new employees. On
Senseonics Holdings, Inc. (NYSE American: SENS) announced updates regarding their next-generation Eversense 180-day continuous glucose monitoring (CGM) system. The FDA's review for the PMA supplement is nearing completion, with a decision expected soon. The company is working with Ascensia Diabetes Care to ensure a smooth transition to the new system, including marketing campaigns and reimbursement plans. Senseonics maintains its revenue outlook for 2021, projecting net revenues between $12 million and $15 million.
Senseonics Holdings, Inc. (SENS) announced the receipt of the CE mark for its Eversense NOW Remote Monitoring App for Android, enhancing its long-term continuous glucose monitoring system. The app, which offers real-time glucose data monitoring for users and their families, is expected to launch in Q1 2022. The Eversense XL CGM System allows glucose measurement for up to 180 days. The company emphasizes its commitment to transforming diabetes management with innovative technology.
Senseonics Holdings, Inc. (SENS) reported third quarter 2021 revenue of $3.5 million, a significant increase from $0.8 million in Q3 2020. U.S. revenue was $0.6 million, while international sales reached $2.9 million. The net income surged to $42.9 million or $0.10 per share, a turnaround from a net loss of $23.4 million a year prior. However, the company anticipates 2021 global net revenue to fall within $12 million to $15 million due to uncertainties related to COVID-19 and FDA reviews.
Senseonics Holdings, Inc. (AMEX: SENS) has announced participation in two upcoming investor conferences. Management will engage in a virtual fireside chat on November 16, 2021, at 8:40am ET during the Stifel 2021 Virtual Healthcare Conference. Additionally, a presentation will be available on November 18, 2021, at 3:00am ET at the Jefferies London Healthcare Conference. Interested parties can access live and on-demand webcasts on the Company’s website. Senseonics focuses on long-term glucose monitoring systems for diabetes management.
Senseonics Holdings, Inc. (AMEX: SENS) has announced plans to release its third quarter 2021 financial results on November 9, 2021, after market close. A conference call will be held at 4:30 p.m. Eastern Time to discuss the company's performance for the quarter. Investors can access the webcast through Senseonics' website. The company specializes in developing long-term, implantable continuous glucose monitoring systems aimed at improving diabetes management.
Senseonics Holdings, Inc. (NYSE American: SENS) announced equity grants under its 2019 Inducement Plan to 11 new non-executive employees as of October 1, 2021. A total of 74,000 non-qualified stock options were granted at an exercise price of $3.45 per share, the closing price on the grant date. The options vest 25% on the first anniversary of employment, with the remainder vesting monthly over three years, dependent on continued service. Senseonics aims to expand its Eversense Continuous Glucose Monitoring (CGM) System for diabetes management.
The University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio, has commenced offering the Eversense® Continuous Glucose Monitoring (CGM) System to Medicare enrollees as of early September 2021. This initiative aims to improve diabetes management among patients with type 1 and type 2 diabetes who are on insulin. The Eversense CGM System, which features a long-term implantable sensor and a smart transmitter, enhances patient experience and supports better health outcomes, as emphasized by Betul Hatipoglu, M.D. at UHACO.
FAQ
What is the current stock price of Senseonics (SENS)?
What is the market cap of Senseonics (SENS)?
